Total Payments
$25,294
2024 Payments
$3,599
Companies
66
Transactions
1,010
Medicare Patients
12,335
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$22,720 (89.8%)
Travel$2,121 (8.4%)
Education$320.34 (1.3%)
Other$84.15 (0.3%)
Consulting$48.54 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $22,720 | 990 | 89.8% |
| Travel and Lodging | $2,121 | 8 | 8.4% |
| Education | $320.34 | 10 | 1.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $84.15 | 1 | 0.3% |
| Consulting Fee | $48.54 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $3,046 | 42 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $2,222 | 135 | $0 (2024) |
| HEARTFLOW, INC. | $2,020 | 21 | $0 (2024) |
| Medtronic Vascular, Inc. | $1,913 | 16 | $0 (2020) |
| Amgen Inc. | $1,514 | 112 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,346 | 89 | $0 (2024) |
| PFIZER INC. | $929.94 | 55 | $0 (2024) |
| GENZYME CORPORATION | $795.37 | 34 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $744.32 | 36 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $623.55 | 40 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,599 | 88 | HEARTFLOW, INC. ($1,242) |
| 2023 | $2,352 | 103 | Alnylam Pharmaceuticals Inc. ($210.40) |
| 2022 | $3,578 | 152 | Janssen Pharmaceuticals, Inc ($458.91) |
| 2021 | $3,015 | 158 | Novartis Pharmaceuticals Corporation ($420.69) |
| 2020 | $2,143 | 90 | Medicure Pharma Inc. ($424.00) |
| 2019 | $3,066 | 143 | Janssen Pharmaceuticals, Inc ($431.42) |
| 2018 | $4,738 | 152 | Medtronic Vascular, Inc. ($1,648) |
| 2017 | $2,801 | 124 | Abbott Laboratories ($676.51) |
All Payment Transactions
1,010 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Abbott Laboratories | MITRACLIP (Device) | Food and Beverage | In-kind items and services | $137.85 | General |
| Category: Vascular | ||||||
| 12/19/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $21.99 | General |
| Category: Cardiology | ||||||
| 12/18/2024 | Itamar Medical Inc | WatchPATONE (Device) | Food and Beverage | Cash or cash equivalent | $19.52 | General |
| Category: Sleep Apnea testing | ||||||
| 12/10/2024 | Abbott Laboratories | XIENCE SKYPOINT (Device) | Food and Beverage | In-kind items and services | $120.69 | General |
| Category: Vascular | ||||||
| 12/05/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $106.30 | General |
| Category: Coronary | ||||||
| 12/02/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Cardiology | ||||||
| 11/25/2024 | Recor Medical Inc | PARADISE RENAL DENERVATION SYSTEM (Device) | Food and Beverage | Cash or cash equivalent | $20.09 | General |
| Category: Endovascular | ||||||
| 11/22/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/11/2024 | Azurity Pharmaceuticals, Inc. | EDARBYCLOR (Drug) | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/08/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: Cardiology | ||||||
| 10/31/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $22.01 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 10/24/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $20.39 | General |
| Category: Cardiovascular | ||||||
| 10/24/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $20.39 | General |
| Category: Cardiovascular | ||||||
| 10/24/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $12.12 | General |
| Category: Cardiovascular | ||||||
| 10/22/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $8.13 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 10/21/2024 | Recor Medical Inc | PARADISE RENAL DENERVATION SYSTEM (Device) | Food and Beverage | Cash or cash equivalent | $111.26 | General |
| Category: Endovascular | ||||||
| 10/04/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: Cardiology | ||||||
| 09/27/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/25/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: Genetic Disease | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/17/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/11/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $21.05 | General |
| Category: Cardiovascular | ||||||
| 08/30/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 3,407 | 4,643 | $1.2M | $284,746 |
| 2022 | 31 | 3,228 | 4,516 | $1.3M | $298,616 |
| 2021 | 30 | 2,834 | 4,197 | $1.2M | $297,131 |
| 2020 | 31 | 2,866 | 4,057 | $1.1M | $261,799 |
Total Patients
12,335
Total Services
17,413
Medicare Billing
$1.1M
Procedure Codes
140
All Medicare Procedures & Services
140 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 524 | 722 | $158,840 | $64,950 | 40.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 277 | 286 | $228,800 | $39,838 | 17.4% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 70 | 70 | $175,000 | $23,782 | 13.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 148 | 389 | $58,350 | $23,199 | 39.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 138 | 164 | $45,920 | $14,711 | 32.0% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 80 | 324 | $48,600 | $13,773 | 28.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 110 | 110 | $36,850 | $12,177 | 33.0% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 66 | 66 | $52,800 | $10,914 | 20.7% |
| 92928 | Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | Facility | 2023 | 22 | 27 | $81,000 | $10,691 | 13.2% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 56 | 56 | $28,560 | $7,823 | 27.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 155 | 160 | $39,825 | $7,805 | 19.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 580 | 713 | $33,511 | $7,259 | 21.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 49 | 76 | $17,915 | $6,435 | 35.9% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 31 | 31 | $29,985 | $5,801 | 19.3% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 80 | 81 | $15,390 | $3,978 | 25.8% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 59 | 64 | $23,680 | $3,121 | 13.2% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 100 | 100 | $8,200 | $2,889 | 35.2% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 12 | 101 | $15,150 | $2,794 | 18.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 370 | 440 | $17,600 | $2,775 | 15.8% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 71 | 72 | $28,400 | $2,571 | 9.1% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Office | 2023 | 64 | 64 | $12,160 | $2,521 | 20.7% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 12 | 101 | $13,635 | $1,967 | 14.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 13 | $3,835 | $1,819 | 47.4% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 20 | 21 | $5,775 | $1,642 | 28.4% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 33 | 72 | $9,720 | $1,581 | 16.3% |
About Dr. Mark Peterman, MD
Dr. Mark Peterman, MD is a Cardiovascular Disease healthcare provider based in Plano, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1386752939.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Peterman, MD has received a total of $25,294 in payments from pharmaceutical and medical device companies, with $3,599 received in 2024. These payments were reported across 1,010 transactions from 66 companies. The most common payment nature is "Food and Beverage" ($22,720).
As a Medicare-enrolled provider, Peterman has provided services to 12,335 Medicare beneficiaries, totaling 17,413 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 140 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Nuclear Cardiology, Interventional Cardiology
- Location Plano, TX
- Active Since 08/25/2006
- Last Updated 05/19/2023
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1386752939
Products in Payments
- XARELTO (Drug) $2,222
- FFRct (Device) $1,818
- Resolute (Device) $1,569
- ENTRESTO (Drug) $1,269
- ELIQUIS (Drug) $1,165
- Repatha (Biological) $1,073
- Confirm Rx (Device) $796.18
- NORTHERA (Drug) $622.97
- BRILINTA (Drug) $621.07
- VERQUVO (Drug) $611.76
- LifeVest (Device) $573.60
- Vascepa (Drug) $512.03
- ONPATTRO (Drug) $466.60
- FABRAZYME (Biological) $465.47
- Corlanor (Drug) $440.84
- HMG-CoA reductase inhibitor. (Drug) $424.00
- JARDIANCE (Drug) $388.07
- NEXLETOL (Drug) $342.06
- Quadra Assura CRT Defibrillator (Device) $332.36
- PRALUENT ALIROCUMAB INJECTION (Biological) $319.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Plano
Srinivasa Potluri, Md, MD
Cardiovascular Disease — Payments: $783,265
Cardiovascular Disease $783,265
Dr. David Brown, M.d, M.D
Cardiovascular Disease — Payments: $256,750
Cardiovascular Disease $256,750
David Rawitscher, Md, MD
Cardiovascular Disease — Payments: $244,805
Cardiovascular Disease $244,805
Sahil Bakshi, Do, DO
Cardiovascular Disease — Payments: $193,440
Cardiovascular Disease $193,440
Mordecai Klein, Md, MD
Cardiovascular Disease — Payments: $162,433
Cardiovascular Disease $162,433
Dr. Vijay Ramanath, M.d, M.D
Cardiovascular Disease — Payments: $123,142
Cardiovascular Disease $123,142